RVNC vs. ARDX, NRIX, KNSA, RCUS, MRVI, OCUL, ARVN, CALT, DAWN, and PRAX
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Ardelyx (ARDX), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Maravai LifeSciences (MRVI), Ocular Therapeutix (OCUL), Arvinas (ARVN), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
Revance Therapeutics vs.
Revance Therapeutics (NASDAQ:RVNC) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.
Ardelyx received 130 more outperform votes than Revance Therapeutics when rated by MarketBeat users. Likewise, 67.47% of users gave Ardelyx an outperform vote while only 60.85% of users gave Revance Therapeutics an outperform vote.
97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Revance Therapeutics had 14 more articles in the media than Ardelyx. MarketBeat recorded 23 mentions for Revance Therapeutics and 9 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.58 beat Revance Therapeutics' score of 0.06 indicating that Ardelyx is being referred to more favorably in the news media.
Revance Therapeutics currently has a consensus price target of $8.39, suggesting a potential upside of 127.87%. Ardelyx has a consensus price target of $9.25, suggesting a potential upside of 84.63%. Given Revance Therapeutics' higher possible upside, equities research analysts plainly believe Revance Therapeutics is more favorable than Ardelyx.
Revance Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Ardelyx has lower revenue, but higher earnings than Revance Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ardelyx has a net margin of -28.82% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Ardelyx's return on equity.
Summary
Ardelyx beats Revance Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RVNC) was last updated on 1/21/2025 by MarketBeat.com Staff
Free RVNC Stock Alerts